Study: NCT06145308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma (HER2 expression group) : Vedicetumab (2.5mg/kg, Q2w) alone or combined with platinum-based chemotherapy drugs (carboplatin 200-250mg/m2, Q2w or cisplatin 50mg/m2, Q2w) Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing (HER2 expression group) : Vedicetumab monotherapy (2mg/kg, IV, Q2w) or vedicetumab (2mg/kg, IV, Q2w) combined with immune checkpoint inhibitors (triprilizumab 3mg/kg, IV, Q2w, etc.) or vedicetumab (2mg/kg, IV, Q2W, etc.) Q2w) in combination with oral HER2 TKI (pyrrotinib 400mg po qd and other drugs) or Vedicetsol in combination with platinum-based chemotherapy drugs of the doctor's choice (carboplatin 200-250mg/m2, intravenous drip, Q2w or cisplatin 50mg/m2, intravenous drip, Q2w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larotinib or enttraitinib
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma (NTRK gene fusion or mutant group) : NTRK inhibitors such as larotinib 100mg Bid po or enttraitinib 600mg qd po; Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing (NTRK gene fusion or mutant group) : NTRK inhibitors such as larotinib 100mg Bid po or enttraitinib 600mg qd po;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiandrogen drug treatment
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(AR positive group) : leprerelin 3.75mg subcutaneous injection Q4w+ bicalutamide 80mg qd po ± Abiraterone 1000mg po qdor antiandrogen drug treatment; Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(AR positive group) : leprerelin 3.75mg subcutaneous injection Q4w+ bicalutamide 80mg qd po or antiandrogen drug treatment;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG401
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(TROP-2 positive group) : ESG401 16mg/kg,D1，D8 ,D15 ivgtt Q4w.~Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(TROP-2 positive group) : ESG401 16mg/kg,D1，D8 ,D15 ivgtt Q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: small molecule multi-target tyrosine kinase inhibitors± Chemioterapy
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(ACC group)and Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(ACC group): Adenoid cystadenocarcinoma given acitinib (5mg bid po) or apatinib (500mg qd po) or Renvastinib (24mg qd po) or sorafenib (400mg bid po) or anrotinib (12mg qd) po) or other small molecule multi-target tyrosine kinase inhibitors± chemotherapy(albumin paclitaxel :160mg/m2 Q2w or 260mg/m2 Q3w, combined with platinum-based chemotherapy drugs of the doctor's choice: cisplatin 50mg/m2, Q2w or 75mg/m2, Q3w, or carboplatin 200-250mg/m2 Q2w or 350mg/m2 q3w, static).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin paclitaxel with platinum
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(no target and other groups) : albumin paclitaxel :160mg/m2 Q2w or 260mg/m2 Q3w, combined with platinum-based chemotherapy drugs of the doctor's choice: cisplatin 50mg/m2, Q2w or 75mg/m2, Q3w, or carboplatin 200-250mg/m2 Q2w or 350mg/m2 q3w, ; Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(no target and other groups) : albumin paclitaxel :160mg/m2 Q2w or 260mg/m2 Q3w, combined with platinum-based chemotherapy drugs of the doctor's choice: cisplatin 50mg/m2, Q2w or 75mg/m2, Q3w, or carboplatin 200-250mg/m2 Q2w or 350mg/m2 q3w,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR-positive group
Description: Abesili 150mg bid po or Piperoxili 125mg qd po, etc CDK4/6 inhibitors + aromatase inhibitors (letrozole 2.5mg qd po or anastrozole 1mg qd po or Exemestane 20mg qd po) or Fluvis Group 0.5mg im q4w;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K mutant group
Description: PI3K inhibitors such as Apelis 300mg qd po + Fluvis group 0.5mg im q4w, etc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homologous Recombination repair defect group
Description: Olapalil 300mg bid po or Nilapalil 300mgPARP inhibitors such as qd po or fluzopalil 150mg bid po or pamipalil 60mg bid po;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nectin-4 ADC group
Description: Veentumab 1.25mg/kg ivgtt d1d8d15(Max Nectin-4 ADC± immune checkpoint inhibitor (pabolizumab 200mg, pabolizumab 200mg,Carrilizumab 200mg, Q3w or triplizumab 240mg, Q3w, etc.);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivoximab group
Description: Ivoximab 20mg/kg+ albumin paclitaxel 260mg/m2+Cisplatin 75mg/m2 ivgtt q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalolito vorellizumab group
Description: Apalolito vorellizumab 5mg/kg+ Platinum dual drug (white purple 260mg/m2 Q3w/ Paclitaxel liposome 175mg/m2/ Docetaxel 75mg/m2/ vinorelbine 25mg/m2 + cisplatin 75mg/m2, Q3w or carboplatin 350mg/m2 q3w) + bevacizumab 5mg/kg;